Tenet Healthcare (THC) Q3 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2024 earnings summary
8 Jul, 2026Executive summary
Q3 2024 net operating revenues reached $5.12 billion, with consolidated adjusted EBITDA of $978 million, up 14.5–15% year-over-year, and net income available to shareholders of $472 million, reflecting gains from major hospital divestitures.
Ambulatory segment delivered 18.6–19% adjusted EBITDA growth to $439 million, with robust volume and revenue per case increases; hospital segment adjusted EBITDA grew 11% (24% ex-divestitures).
Major divestitures in Alabama, South Carolina, and California generated $2.9 billion in pre-tax gains and improved the hospital portfolio's return profile.
Free cash flow for Q3 was $829 million, supporting investments and share repurchases; cash on hand at quarter-end was $4.09 billion.
Share repurchases totaled 5.6 million shares for $672 million year-to-date, with a new $1.5 billion program authorized.
Financial highlights
Q3 2024 net operating revenues were $5.12 billion (up 1.1% year-over-year); adjusted EBITDA margin was 19.1%, up from 16.9% in Q3 2023.
Q3 2024 net income was $472 million (9.2% margin); diluted EPS was $4.89, adjusted diluted EPS $2.93.
Free cash flow for Q3 2024 was $829 million, up from $327 million in Q3 2023.
Cash and cash equivalents at September 30, 2024, were $4.09 billion.
Net debt to adjusted EBITDA ratio improved to 2.22x at September 30, 2024.
Outlook and guidance
FY 2024 adjusted EBITDA guidance raised to $3.9–$4.0 billion, with net operating revenues expected at $20.6–$20.8 billion.
FY 2024 free cash flow projected at $975 million to $1.225 billion, with adjusted free cash flow at $1.15–$1.35 billion.
Ambulatory segment FY 2024 net revenue per surgical case expected to rise 6–7%; hospital admissions up 4–5%.
Capital expenditures for 2024 projected at $800–$900 million, focused on ambulatory expansion and hospital upgrades.
Management expects to offset divested facility EBITDA and Medicaid adjustments in 2025 through volume growth, pricing, and efficiencies.
Latest events from Tenet Healthcare
- Q2 2026 profit and margin growth drove higher FY 2026 guidance and a $2B buyback increase.THC
Q2 202625 Jul 2026 - High-acuity focus and disciplined capital deployment drive growth amid policy uncertainty.THC
Barclays 27th Annual Global Healthcare Conference9 Jul 2026 - Q4 and FY 2024 results show margin expansion, deleveraging, and robust ambulatory growth.THC
Q4 20249 Jul 2026 - Q2 2024 Adjusted EBITDA up 12% to $945M; FY 2024 guidance and buybacks increased.THC
Q2 20248 Jul 2026 - Q1 2025 Adjusted EBITDA up 14%, margin gains, strong cash flow, and $348M in buybacks.THC
Q1 20258 Jul 2026 - Sequential volume recovery and high acuity focus drive confidence in annual growth targets.THC
Bank of America Global Healthcare Conference 202613 May 2026 - Q1 2026 net income jumped 73% to $702M, with strong EBITDA and robust cash flow.THC
Q1 20269 May 2026 - 2025 performance exceeded targets, supporting high executive pay and strong shareholder returns.THC
Proxy filing16 Apr 2026 - Virtual meeting to elect 12 directors, approve pay, and ratify auditors, with board support.THC
Proxy filing16 Apr 2026